Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Studies are showing that 26% of patients are losing as much of 30% or more of their base weight
Semaglutide patents extend into the early 2030s, meaning generic competition is still years away
PubMed laboratory research record [PMID: 41651376] PubMed record related to this compound for laboratory literature review
Incretin mimetics (GLP-1 receptor agonists) consistently promote weight loss, with patients typically losing 26 kg over several months, making them particularly valuable for overweight individuals with type 2 diabetes
US$ 22.52
US$ 27.46
US$ 27.31
US$ 26.58
US$ 27.21
US$ 21.71
US$ 24.71
US$ 23.79
US$ 28.77
US$ 28.29
